Cabaletta names ElevateBio as second partner for rese-cel
US biotech Cabaletta Bio (Nasdaq: CABA) has named ElevateBio as a second contract development and manufacturing organization (CDMO) for its lead cell therapy rese-cel (resecabtagene autoleucel), placing a privately held Massachusetts operator alongside Swiss CDMO major Lonza (SIX: LONN) as the candidate moves toward a regulatory filing.
The choice of partner is the notable detail. ElevateBio runs BaseCamp, a cGMP manufacturing and process development business at Waltham, Massachusetts. In January the company said it had lifted capacity at the Waltham site by 30% and completed shell construction on a second facility at Pittsburgh, due to be operational in 2027.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze